Current treatments for the above-mentioned medical conditions constrict blood vessels in an uncontrolled way, rather than preventing their dilation in the first place, and thus cause hypertension. [3,4] MTR-104 normalizes the diameter of blood vessels without the "overshooting" that results in excessive constriction and hypertension. Clinical trials in both Western and Eastern Europe have indicated that TrioxBio's NOS inhibitor is safe and well-tolerated.